Can a hospital team boost HIV care and cut readmissions?
NCT ID NCT05866523
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether a team-based program (called ARTAS) helps people with HIV get connected to care after leaving the hospital and reduces the chance of coming back. The team includes infectious disease doctors and social workers who provide support during the hospital stay and up to 90 days after. The study will enroll 250 adults with HIV who are not currently in regular care.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- team-based behavioral intervention (inpatient consultation and case management)
- What this could lead to
- If successful, this could show that a coordinated team approach in the hospital improves HIV care follow-up and lowers readmission rates.
- What could go wrong
- This is a relatively small, early-stage behavioral study, so results may not apply broadly. Success depends on patient engagement and follow-up, which can be challenging.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 250 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Oct 2023
- Expected to finish
-
Dec 2026
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * 18 years of age or greater * newly diagnosed HIV * Known diagnosis of HIV not on ART within 30 days of admission * Known HIV and not virally suppressed based on interview * Known HIV and has not been under the care of an HIV specialist within the past 6 months Exclusion Criteria: * All three criteria must be present for exclusion: * virally suppressed * actively taking ART * are under active care of an HIV specialist within the last 6 months * Less than 18 years of age (stand alone exclusion)
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIV infections are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Loma Linda University Medical Center
RECRUITINGLoma Linda, California, 92354, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a Three-Session couples program cut drug use and HIV risk?
- Decades of HIV data could reveal which treatments last
- Can testing together again keep male couples HIV-Free?
- Can a rapid HIV test get people treated sooner?
- Can Same-Day HIV prevention reach people before infection takes hold?
- New injectable HIV prevention drug tested in healthy volunteers